Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PROT-RESIST

Financiado

Cerrado

Toward the Commercialization of a Proteolytically Resistant APPI Variant for Inh...

Toward the Commercialization of a Proteolytically Resistant APPI Variant for Inhibiting Metastasis in Prostate and Pancreatic Cancer Distal site tumor metastasis is the leading cause of prostate- and pancreatic-cancer-related deaths; nevertheless, standard-of-care (SoC) treatments and other targeted therapies under development are based on their activity agains... ver más

30/04/2021

BGU

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

BENGURION UNIVERSITY OF THE NEGEV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-04-30

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

BGU

150.00K€ | Lider

Alcad, SL

118.80K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MICROENVIMET Understanding and fighting metastasis by modulating the tumo... 4M€ Cerrado

SAF2013-48657-R MODULACION DE LA PROGRESION TUMORAL POR ENZIMAS PI3K: APROXI... 484K€ Cerrado

RTI2018-096455-B-I00 INHIBIDORES DE TIROSINA QUINASAS DUALES EN CANCER DE PANCREA... 157K€ Cerrado

PID2020-120110RA-I00 DEGRADACION Y LOCALIZACION DIRIGIDA DE PROTEINAS: NUEVAS SOL... 190K€ Cerrado

PDC2021-121119-I00 PEPTIDOMIMETICOS INHIBIDORES DE KRAS COMO TERAPIA DIRIGIDA P... 148K€ Cerrado

Bcl-Inhib Discovery of Bcl 3 inhibitors as Potential Chemopreventive A... 150K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2019-10-28
Fecha Fin: 2021-04-30

Líder del proyecto

BENGURION UNIVERSITY OF THE NEGEV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Distal site tumor metastasis is the leading cause of prostate- and pancreatic-cancer-related deaths; nevertheless, standard-of-care (SoC) treatments and other targeted therapies under development are based on their activity against the primary tumors rather than on their anti-metastatic activity. There is consequently an urgent medical need for new agents targeting the metastatic process. In prostate and pancreatic cancer models, the serine protease mesotrypsin promotes tumor invasion and metastasis, making it an attractive target for therapeutic intervention. In our ERC StG project, we used directed evolution to generate a novel prototype mesotrypsin inhibitor, designated APPI-3M, which is based on the human amyloid β-protein precursor Kunitz protease inhibitor domain (APPI) scaffold. This inhibitor has picomolar affinity, enhanced binding specificity and improved proteolytic resistance to mesotrypsin and exhibits high potency in cell-based and preclinical models of prostate cancer invasion and metastasis. In this PoC proposal, we propose to perform final lead optimization (particularly decreasing body clearance) of APPI-3M towards its commercialization for clinical translation as an antimetastatic therapeutic adjuvant, with the direct involvement in the planning stage of clinicians and other key opinion leaders in the field. The feedback of these experts is expected to confirm the need to address the problem of metastatic progression and to identify potential indications and therapeutic windows for the use of APPI-3M as a neoadjuvant in prostate and pancreatic cancers. This input will be translated into feasible preclinical studies to demonstrate the contribution of APPI-3M therapy to currently ongoing SoC protocols for prostate and pancreatic cancers. In parallel, we will carry out the in-depth market and IP analyses needed for the commercialization of the engineered protein for therapeutic applications.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores